2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia : make it concise
Searching the Web
2026 ACC AHA dyslipidemia guideline management
Searching PubMed
ACC AHA dyslipidemia guideline 2026
Reading Web Page
https://www.guidelinecentral.com/guideline/5099440/pocket-gu…
Reading Web Page
https://www.lipid.org/nla/2026-accahamultisociety-dyslipidem…
2026 ACC/AHA Multisociety Guideline on the Management of Dyslipidemia - Concise Summary
Published: March 13, 2026 | Replaces: 2018 AHA/ACC Blood Cholesterol Guideline | PMID: 41824590
Key Changes from 2018
| Feature | 2018 Guideline | 2026 Guideline |
|---|---|---|
| LDL-C goals | Avoided numeric targets | Explicit numeric goals restored |
| Risk calculator | Pooled Cohort Equations (PCE) | PREVENT-ASCVD equations |
| Lp(a) screening | Optional | Class I (universal, once in adulthood) |
| Scope | Blood cholesterol | Dyslipidemia (LDL-C + TG + Lp(a)) |
LDL-C Treatment Goals (Restored)
| Risk Category | LDL-C Goal | Non-HDL-C Goal |
|---|---|---|
| Very high-risk ASCVD (secondary prevention) | <55 mg/dL | <85 mg/dL |
| ASCVD not at very high risk | <70 mg/dL | <100 mg/dL |
| Borderline/intermediate primary prevention | <100 mg/dL | <130 mg/dL |
| CAC ≥1000 AU | <55 mg/dL | <85 mg/dL |
| CAC 300-999 AU | <70 mg/dL | <100 mg/dL |
| CAC 100-299 AU or ≥75th percentile | <70 mg/dL | <100 mg/dL |
A ≥50% LDL-C reduction from baseline is an additional goal for high- and very-high-risk patients.
Risk Assessment: PREVENT-ASCVD Equations
- Replace the Pooled Cohort Equations for adults aged 30-79 years
- Provide both 10-year and 30-year ASCVD risk estimates
- PCE overestimated 10-year risk by ~40-50% in contemporary cohorts
- Primary prevention LLT considerations:
- 10-year risk 3-<5% (borderline): LLT may be considered after clinician-patient discussion
- 10-year risk 5-<10% (intermediate): LLT should be considered
- 10-year risk ≥10% (high): LLT recommended
Lipoprotein(a) - Now Class I
- Universal Lp(a) measurement at least once in all adults - Class I recommendation
- Lp(a) >125 nmol/L (>50 mg/dL) is an ASCVD risk enhancer
- Children <18 years: special considerations for testing if family history of premature ASCVD or FH
- Pelacarsen (Lp(a)-lowering RNA therapy) under FDA review; not yet in standard algorithm
Treatment Algorithm
Step 1: Lifestyle (All Patients)
- Heart-healthy eating (Mediterranean or plant-based pattern)
- Regular physical activity
- Avoid all nicotine products
- Healthy weight and sleep (aligned with AHA Life's Essential 8™)
- Stress management
Step 2: First-Line Pharmacotherapy
Statins remain the cornerstone - maximize tolerated dose first
Step 3: Add-On Therapies (when LDL-C goal not met)
Listed in order of evidence/positioning:
- Ezetimibe - ~18-25% additional LDL-C reduction; Class I in high-risk
- Bempedoic acid - ~18-22% LDL-C reduction; Class I in statin intolerance, equal positioning with ezetimibe in primary and secondary prevention not at very high risk
- PCSK9 inhibitors (evolocumab, alirocumab) - ~50-60% reduction; Class I in very high-risk ASCVD
- Inclisiran (siRNA) - ~50% reduction; expanded indications; same efficacy tier as PCSK9 mAbs
Early combination therapy ("lower for longer") is explicitly endorsed - cumulative LDL-C burden matters.
Hypertriglyceridemia
- Normal TG: <150 mg/dL
- Elevated TG: 150-499 mg/dL - lifestyle intervention first; statin if ASCVD risk present
- Severe TG: ≥1000 mg/dL - TG-lowering therapy to prevent pancreatitis (fibrates, omega-3 fatty acids, niaspan)
- Statin remains the foundation of pharmacotherapy for ASCVD risk reduction even in elevated TG
Severe Hypercholesterolemia (LDL-C ≥190 mg/dL)
- Exclude secondary causes first
- Maximally tolerated statin - Class I
- Add ezetimibe - Class I
- Add PCSK9 inhibitor/inclisiran if goal not met
- Consider evinacumab (ANGPTL3 inhibitor) for homozygous FH (HoFH)
Special Populations
| Population | Key Point |
|---|---|
| Children | Lipid screening recommended; FH cascade testing emphasized |
| Diabetes (DM) | DM itself is an ASCVD risk enhancer; LLT threshold lowered |
| Women | Pregnancy-specific guidance; menopause as risk enhancer |
| Elderly (≥75 yrs) | Individualize; benefit continues; AGS co-endorsement |
| CKD | ASCVD risk enhancer; statin/ezetimibe preferred |
Coronary Artery Calcium (CAC) Scoring
- Remains a valuable risk reclassifier for primary prevention
- CAC=0 supports deferral of pharmacotherapy (except in DM, smoking, strong family history)
- CAC guides intensity of LLT (see LDL-C goals table above)
Referral to Lipid Specialist
Expressly recommended for:
- HoFH or severe/refractory hypercholesterolemia
- Persistently very high Lp(a)
- Complex mixed dyslipidemias
- Recurrent ASCVD events despite maximally tolerated LLT
Bottom Line
The 2026 guideline makes three headline shifts: (1) explicit LDL-C numeric targets are back; (2) PREVENT equations replace the PCE for more accurate risk estimation; and (3) Lp(a) screening is now a standard-of-care Class I recommendation. The therapeutic ladder - statin → ezetimibe/bempedoic acid → PCSK9 inhibitors/inclisiran - is now formally endorsed under guideline authority, with "lower for longer" as the overarching philosophy.
This is a shared conversation. Sign in to Orris to start your own chat.